# 100. TOPICAL STEROIDS C

447
DERM
8.1 Ed. Authors/Editors
Laurie Hommema, MD
Emily Gorman, DO
100. TOPICAL STEROIDS
Classification of Topical Steroid Preparations by Potency
Drug
Brand Name(s)
Strength/
Formulation
Size
Dosing
Frequency
Group I (Super High Potency)#
Betamethasone dipropionate,
augmented
Diprolene, generic
0.05% O, G
15g
daily-bid
Clobetasol propionate
Clobex, Temovate, Olux, generic
0.05% O, C, S, G,
F, Sh, Spray
C, G: 30, 60g
F: 50g
L, Spray: 59mL
S: 50mL
O: 15, 30g
Sh: 118mL
bid
Fluocinonide
Vanos
0.1% C
30, 60g
bid-4 ×/day
Halobetasol propionate
Ultravate, generic
0.05% O, C
15, 50g
daily-bid
Group II (High Potency)
Amcinonide
Cyclocort
0.1% O
60g
bid-tid
Betamethasone dipropionate,
augmented
Diprolene AF, generic
0.05% C
15g
daily-bid
Betamethasone dipropionate
Diprosone, generic
0.05% O
15g
daily-bid
Desoximetasone
Topicort, generic
0.25% O, C
60g
bid
0.05% G
15g
bid
Topicort, generic
Diflorasone diacetate
ApexiCon, generic
0.05% O
30g
bid
Fluocinonide
Vanos, generic
0.05% O, C, S
C: 30, 60g
G: 60g
O: 30g
S: 60mL
bid-tid
Halcinonide
Halog
0.1% O, C
O: 30g
C: 60g
daily-tid
Mometasone Furoate
Elocon, generic
0.1% O
15g
daily
Triamcinolone acetonide
Trianex, generic
0.5% O
15g
bid-tid
Group III (Medium-High Potency)
Amcinonide
Cyclocort
0.1% C, L
C:30g
L: 60mL
bid-tid
Betamethasone dipropionate
Diprosone, generic
0.05% C
15g
daily-bid
Betamethasone valerate
Betatrex, generic
0.1% O
15g
daily-bid
Desoximetasone
Topicort LP, generic
0.05% C, G, O
15, 60g
bid
Diflorasone diacetate
ApexiCon, generic
0.05% C
30, 60g
bid
Fluticasone propionate
Cutivate, generic
0.005% O
30g
daily-bid
Triamcinolone acetonide
Trianex, generic
0.1% O
15g
bid-tid
Tridem, generic
0.5% C
15g
bid-tid
Group IV (Medium potency)
Betamethasone valerate
Luxiq, generic
0.12% F
50g
Fluocinolone acetonide
Synalar, generic
0.025% O
15, 120g
bid-tid
448
DERM
O=ointment, C=cream, L=lotion, S=solution, G=gel, F=foam Sh=shampoo
Hydrocortisone valerate
Westcort, generic
0.2% O
45g
bid-tid
Mometasone furoate
Elocon, generic
0.1% C
15, 45g
daily
Triamcinolone acetonide
Triderm, generic
0.1% C
15 , 28.4g
bid-tid
Trianex
0.05% O
17g
bid-tid
Group V ( Medium-Low Potency)
Betamethasone dipropionate
Diprolene, generic
0.05% L
30, 60ml
Betamethasone valerate
Betatrex, generic
0.1% C
45g
daily-bid
Desonide
DesOwen, generic
0.05% O
15, 60g
bid-4 ×/day
Flurandrenolide
Cordran
0.05% C, L
C:30g
L: 60mL
bid-4 ×/day
Fluticasone propionate
Cutivate, generic
0.05% C
30g
daily-bid
Fluocinolone acetonide
Synalar, generic
0.025% C
15, 120g
bid-4 ×/day
Hydrocortisone butyrate
Locoid, generic
0.1% O, C, S
O, C:15g
S: 60mL
bid-tid
Hydrocortisone valerate
Westcort, generic
0.2% C
45g
bid-tid
Prednicarbate
Dermatop, generic
0.1% C, O
15, 60g
bid
Triamcinolone acetonide
Kenalog, generic
0.1% L
60mL
bid-tid
0.025% O
80g
Group VI ( Low Potency)
Alclometasone dipropionate
Aclovate, generic
0.05% C, O
C: 15, 45g
O: 45g
bid-tid
Betamethasone valerate
Betatrex, generic
0.01% L
60ml
daily-bid
Clocortolone pivalate
Cloderm
0.1% Pump
30g
tid
Desonide
DesOwen, generic
0.05% C, L, F
C: 15, 60g
L: 59mL
F: 50g
bid-4 ×/day
Fluocinolone acetonide
Synalar, generic
0.01% C, S
C: 15g
S: 60mL
bid-4 ×/day
Triamcinolone acetonide
Triderm, generic
0.025% C, L
C: 15g
L: 60mL
bid-tid
Group VII (Lowest Potency)
Hydrocortisone
Proctosol, generic
2.5% C, O, L
C: 28, 30g
O: 28g
bid-tid
Hydrocortisone
Cortizone, generic
1.0% C, O, L
C, O: 28g
L: 59, 118mL
bid-tid
Hydrocortisone
Cortizone, generic
0.5% C
28g
bid-tid
#Max 50g/week, limit use to 2 week duration, not to use on the face or groin
This table is provided as an information resource only and does not replace the use of clinical judgment.
References
Dack KN, Johnson PS, Henriksson K, et al. Topical ‘dual-soft’ glucocorticoid receptor
agonist for dermatology. Bioorg Med Chem Lett 2020;30(17):127402. doi: 10.1016/j.
bmcl.2020.127402. Epub 2020 Jul 13.PMID: 32738970.
Hashim PW, Chen T, Hebert AA, et al. Topical treatment for the management of atopic dermatitis. J
Drugs Dermatol. 2019 Feb 1;18(s2):s112-s116.PMID: 30811155.
Nakamura M, Abrouk M, Zhu H, et al. Update on the systemic risks of superpotent topical steroids.
J Drugs Dermatol 2017;16(7):643-48.PMID: 28697215.
Phan K, Smith SD. Topical corticosteroids and risk of diabetes mellitus: Systematic
review and meta-analysis. J Dermatolog Treat 2021;32(3):345-49. doi:
10.1080/09546634.2019.1657224. Epub 2019 Aug 25.PMID: 31418613.
